StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) stock

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)

Close on Nov 17, 2026Market cap $666.15MP/E –Yield –

Fulgent Genetics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Fulgent Genetics's price to sales ratio was 2.2× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 1.1× to 3.2×, with a median of 2.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.2×−0.4
2025Dec 31, 20252.6×+0.5
2024Dec 31, 20242.0×−1.0
2023Dec 29, 20233.0×+1.9
2022Dec 30, 20221.1×−1.8
2021Dec 31, 20212.9×−6.1
2020Dec 31, 20209.0×+0.9
2019Dec 31, 20198.1×+5.2
2018Dec 31, 20182.9×−1.0
2017Dec 29, 20173.8×−5.9
2016Dec 30, 20169.7×–

More Fulgent Genetics figures

See a number that looks wrong?